Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Consensus Recommendation of “Hold” by Analysts

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has been given an average recommendation of “Hold” by the five research firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $41.00.

ETON has been the subject of several research analyst reports. Craig Hallum upped their price target on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, March 20th. Wall Street Zen raised shares of Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. HC Wainwright upped their price target on shares of Eton Pharmaceuticals from $52.00 to $57.00 and gave the stock a “buy” rating in a research report on Friday, May 15th. B. Riley Financial upped their price target on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, March 20th. Finally, Zacks Research lowered shares of Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 17th.

Eton Pharmaceuticals Stock Performance

Shares of ETON stock opened at $31.86 on Friday. Eton Pharmaceuticals has a one year low of $13.09 and a one year high of $35.66. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.88 and a current ratio of 1.21. The company has a 50 day moving average price of $26.85 and a 200 day moving average price of $20.14. The firm has a market capitalization of $872.65 million, a price-to-earnings ratio of -455.08 and a beta of 0.82.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Thursday, May 14th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.05). Eton Pharmaceuticals had a negative return on equity of 5.68% and a negative net margin of 1.70%.The company had revenue of $24.27 million for the quarter, compared to analyst estimates of $22.31 million. Sell-side analysts anticipate that Eton Pharmaceuticals will post 0.82 EPS for the current year.

Insider Activity

In related news, insider David Krempa sold 19,679 shares of Eton Pharmaceuticals stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $31.47, for a total transaction of $619,298.13. Following the transaction, the insider owned 25,249 shares in the company, valued at approximately $794,586.03. The trade was a 43.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 100,000 shares of company stock valued at $3,229,921 over the last ninety days. 16.49% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Eton Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. State of Alaska Department of Revenue acquired a new stake in Eton Pharmaceuticals during the 3rd quarter valued at $30,000. Quarry LP acquired a new stake in Eton Pharmaceuticals during the 3rd quarter valued at $37,000. Caitong International Asset Management Co. Ltd acquired a new stake in Eton Pharmaceuticals during the 4th quarter valued at $44,000. Legal & General Group Plc acquired a new stake in Eton Pharmaceuticals during the 2nd quarter valued at $41,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Eton Pharmaceuticals during the 4th quarter valued at $74,000. 27.86% of the stock is owned by institutional investors and hedge funds.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.